From Discovery To Development To Delivery
AZBio is committed to building a top-tier life science industry in Arizona.
Arizona’s bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona’s universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity.
AZBio Members Are Making LIFE Bettter
AZBio Members discover, develop, and deliver life-saving and life-changing innovations.
Get Connected With Arizona's Bioindustry
A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.
Success Stories – Good News from Arizona’s BioIndustry
Convoy Therapeutics, a late pre-approval stage biotechnology company using its proprietary transdermal molecule delivery platform to enhance penetration of large molecules, and retention of small molecules into skin and cells announced today they have entered into a multi-million dollar co-development partnership for exclusive South Korean market rights to Convoy’s Khalay HATM featuring HylaRegenesisTM technology.
Pancreatic cancer patient survival is ‘significantly higher’ with nab-paclitaxel, in study led by TGen and Scottsdale Healthcare
NEJM today publishes findings of international trial resulting in recent FDA approval of Abraxane (nab-paclitaxel) for patients with advanced pancreatic cancer.
As a member of the Council of State Bioindustry Associations, AZBio is please to share this update with our AZBio Membership.
Regenesis Biomedical profiled in BioPharm Insight…